Логотип Репозиторијума
  • English
  • Српски
  • Srpski
  • Пријави се
    Нови корисник? Кликните овде да бисте се регистровали.Јесте ли заборавили лозинку?
  • Заједнице & Колекције
  • Комплетан Репозиторијум
  1. Старт
  2. Прегледај по аутору

Прегледај по Аутор "Radivčev, Aleksandar"

Сада се приказује 1 - 1 од 1
Резултати по страници
Опције сортирања
  • Учитавање...
    Сличица
    Ставка
    Antiphospholipid Antibodies and Vascular Thrombosis in Patients with Severe Forms of COVID-19
    (MDPI, 2023) Zlatković-Švenda, Mirjana; Ovuka, Milica; Ogrič, Manca; Čučnik, Saša; Žigon, Polona; Radivčev, Aleksandar; Zdravković, Marija; Radunović, Goran
    Antiphospholipid antibodies (aPLA) are a laboratory criterion for the classification of antiphospholipid syndrome (APS) and are known to cause clinical symptoms such as vascular thrombosis or obstetric complications. It is suggested that aPLA may be associated with thromboembolism in severe COVID-19 cases. Therefore, we aimed to combine clinical data with laboratory findings of aPLA at four time points (admission, worsening, discharge, and 3-month follow-up) in patients hospitalized with COVID-19 pneumonia. In 111 patients with COVID-19 pneumonia, current and past history of thrombosis and pregnancy complications were recorded. Nine types of aPLA were determined at four time points: anticardiolipin (aCL), anti- 2-glycoprotein I (anti- 2GPI), and antiphosphatidylserine/ prothrombin (aPS/PT) of the IgM, IgG, or IgA isotypes. During hospitalization, seven patients died, three of them due to pulmonary artery thromboembolism (none were aPLA positive). Only one of the five who developed pulmonary artery thrombosis was aPLA positive. Out of 9/101 patients with a history of thrombosis, five had arterial thrombosis and none were aPLA positive at admission and follow-up; four had venous thrombosis, and one was aPLA positive at all time points (newly diagnosed APS). Of these 9/101 patients, 55.6% were transiently aPLA positive at discharge only, compared to 26.1% without a history of thrombosis (p = 0.041). Patients with severe forms of COVID-19 and positive aPLA should receive the same dose and anticoagulant medication regimen as those with negative aPLA because those antibodies are mostly transiently positive and not linked to thrombosis and fatal outcomes.
Адреса
Вука Караџића 30,
71126 Лукавица, Источно Сарајево,
Република Српска
БиХ
Контакт
+387 57 320 330
univerzitet@ues.rs.ba
https://www.ues.rs.ba
понедељак-петак: 07.30 - 15.30
Корисничка подршка
Универзитетски рачунарски центар
+387 57 320 140
urc@ues.rs.ba
https://urc.ues.rs.ba

DSpace software copyright © 2002-2025 LYRASIS

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback